Infantile hemangiomas are the most common benign tumors in infants and children. They typically appear days to weeks after birth, then rapidly proliferate and enter a receding phase around 1 year of age, with a remission period of up to several years. The incidence in girls is 3-5 times higher than that in boys. 1. Since infantile hemangioma can recede naturally, does it still need treatment? Although it has the possibility of receding, hemangiomas that grow rapidly in special areas, such as around the eyes and lips, need to be treated in order to avoid adverse consequences. For infant hemangiomas that are not growing in special areas and are growing slowly, we can closely observe their color, size, texture, growth rate, etc. If necessary, we can go to the hospital regularly for follow-up observation, and a professional physician can help to judge the growth situation. 2.What are the treatment methods? How to choose? There are many clinical methods to intervene in hemangioma, such as oral or injectable medication (propranolol, hormone, vincristine, interferon, etc.), local injection therapy (hormone, pinyamycin, polyglaucine, etc.), topical medication (such as imiquimod, etc.), laser, isotope, cold east, surgery and other treatment options. The above methods are applied for each type of hemangioma or vascular malformation. Different types of methods are used for different types of hemangiomas and sometimes a combination is needed. For strawberry hemangioma in infants and children, laser is the preferred method and has good treatment effect. 3.Is propranolol safe to be taken orally? Propranolol has been used for the treatment of infantile hemangiomas since 2008, but there is still considerable disagreement about the timing of treatment and duration of use. It is a non-selective beta-blocker used clinically for the treatment of heart disease. No serious adverse reactions have been reported for the treatment of hemangioma, but adverse reactions such as lower blood pressure, slower heart rate, hyperkalemia, hypoglycemia, nausea and vomiting, drowsiness, irritability, increased transaminases, temporary respiratory distress, cold extremities, rash, diarrhea and recurrence of lesions may occur during the treatment process and need to be close observation. The indications are as follows: (1) rapid growth, tumor compression or impact on appearance; (2) involvement of important areas or organs, such as the periocular area, parotid area, lip, and subvocal area; (3) multiple hemangiomas throughout the body; (4) giant segmental hemangiomas; (5) HACE syndrome, a neurocutaneous syndrome involving the skin, brain, eyes and ventral side of the body, including posterior cranial fossa vascular malformation, facial angiomas, arterial anomalies, aortic stenosis and/or cardiac defects, ocular anomalies, and sternal fissures. For infants and children with small lesions and no combined deep hemangioma or vascular malformation with slow proliferation, oral propranolol treatment is not considered to avoid overtreatment, which may instead have adverse consequences for the child.